Program
vorolanib
Also written as “EYP-1901”, “CM082” and “CM082 plus JS001”.
Its studies are mostly in Macular Degeneration · Macular Edema · Carcinoma, Renal Cell · Diabetic Retinopathy · Neoplasms, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Betta Pharmaceuticals | 141 open or running | phase 3since Mar 23, 2017 | May 22, 2013 | Jun 2027phase 1 · NCT07809802 |
| EyePoint Pharmaceuticals | 84 open or running | phase 3since Oct 30, 2024 | Feb 6, 2021 | Oct 2027phase 3 · NCT07449923 |
| Tyrogenex | 20 open or running | phase 2since Jan 21, 2015 | Feb 14, 2011 | none ahead |
Also a collaborator on its studies: synteracthcr.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 8 studies since Feb 14, 2011.
- Oct 15, 2018Phase 2 study in Macular DegenerationBetta Pharmaceuticals · NCT03710863 · 64 enrolled · China
- Dec 26, 2018Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT03792958 · 19 enrolled · China
- Feb 19, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungBetta Pharmaceuticals · NCT03848611 · 20 enrolled · China
- Apr 4, 2019Phase 2 study in Small Cell Lung CarcinomaBetta Pharmaceuticals · NCT03904719 · 30 enrolled · China
- Jan 7, 2020Phase 1 study in Myopic Choroidal NeovascularisationBetta Pharmaceuticals · NCT04222842 · 96 enrolled · China
- Mar 26, 2020Phase 1 study in Advanced Malignant Solid TumorsBetta Pharmaceuticals · NCT04328506 · 96 enrolled · China
- Jun 12, 2020Phase 1 study in Advanced Solid TumorBetta Pharmaceuticals · NCT04434326 · 4 enrolled · China
- Feb 6, 2021EyePoint Pharmaceuticals's first study: phase 1 study in Wet Age-related Macular DegenerationNew to EyePoint PharmaceuticalsEyePoint Pharmaceuticals · NCT04747197 · 17 enrolled · United States
- May 9, 20222 phase 2 studiesEyePoint Pharmaceuticals · NCT05381948, NCT05383209
- Oct 19, 2023Phase 2 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT06099184 · 27 enrolled · United States
- Oct 30, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06668064 · 400 enrolled · United States
- Nov 8, 2024Phase 3 study in Wet Age Related Macular DegenerationEyePoint Pharmaceuticals · NCT06683742 · 400 enrolled · United States, Brazil, Czechia and more
- Feb 27, 20262 phase 3 studies in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936, NCT07449923
- Sep 3, 2026Phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802 · 36 planned · China
Ahead
- Jun 2027Primary completion: phase 1 study in Hepatic Impairment (HI)Betta Pharmaceuticals · NCT07809802
- Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449936
- Oct 2027Primary completion: phase 3 study in Diabetic Macular EdemaEyePoint Pharmaceuticals · NCT07449923
TargetBeta
“Vorolanib, a next-generation vascular endothelial growth factor receptor (VEGFR)-targeted tyrosine kinase inhibitor (TKI), exhibits unique pharmacodynamic properties that warrant investigation in adjuvant paradigms.”study text, by rule · the study
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| Ramucirumabrule | Eli Lilly | phase 3 | 58 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
All 24 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07809802Hepatic Impairment (HI) · China | 1 | Recruiting | Betta Pharmaceuticals | Jun 2027 | 36 |
| NCT07449936Diabetic Macular Edema · United States, Germany, Israel and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Oct 2027 | 240 |
| NCT07449923Diabetic Macular Edema · United States, Brazil, Czechia and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Oct 2027 | 240 |
| NCT06683742Wet Age Related Macular Degeneration · United States, Brazil, Czechia and more | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Sep 9, 2026 | 400 |
| NCT06668064Wet Age Related Macular Degeneration · United States | 3 | Active, not recruiting | EyePoint Pharmaceuticals | Jul 13, 2026 | 400 |
| NCT06099184Diabetic Macular Edema · United States | 2 | Completed | EyePoint Pharmaceuticals | Oct 24, 2024 | 27 |
| NCT05383209Nonproliferative Diabetic Retinopathy · United States | 2 | Completed | EyePoint Pharmaceuticals | Feb 12, 2024 | 77 |
| NCT05381948Wet Age-related Macular Degeneration · United States | 2 | Completed | EyePoint Pharmaceuticals | Nov 29, 2023 | 161 |
| NCT04747197Wet Age-related Macular Degeneration · United States | 1 | Completed | EyePoint Pharmaceuticals | May 11, 2022 | 17 |
| NCT04434326Advanced Solid Tumor · China | 1 | Completed | Betta Pharmaceuticals | Oct 22, 2021 | 4 |
| NCT04328506Advanced Malignant Solid Tumors · China | 1 | Completed | Betta Pharmaceuticals | Jul 27, 2020 | 96 |
| NCT04222842Myopic Choroidal Neovascularisation · China | 1 | Suspended | Betta Pharmaceuticals | Dec 30, 2021 | 96 |
| NCT03904719Small Cell Lung Carcinoma · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jun 30, 2021 | 30 |
| NCT03848611Carcinoma, Non-Small-Cell Lung · China | 2 | UNKNOWN | Betta Pharmaceuticals | Feb 2021 | 20 |
| NCT03792958Advanced Malignant Solid Tumors · China | 1 | UNKNOWN | Betta Pharmaceuticals | Jun 2023 | 19 |
| NCT03710863Macular Degeneration · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jan 1, 2022 | 64 |
| NCT03602547Mucosal Melanoma · China | 2 | UNKNOWN | Betta Pharmaceuticals | Jul 2019 | 40 |
| NCT03286244Advanced Gastric Cancer · China | 1 | UNKNOWN | Betta Pharmaceuticals | Aug 2019 | 21 |
| NCT03095040Renal Cell Cancer Metastatic · China | 3 | UNKNOWN | Betta Pharmaceuticals | Feb 2021 | 390 |
| NCT02577458Renal Cell Carcinoma Recurrent · China | 1 | UNKNOWN | Betta Pharmaceuticals | Mar 2018 | 18 |
| NCT02452385Macular Degeneration · China | 1 | Suspended | Betta Pharmaceuticals | Jun 2020 | 56 |
| NCT02348359Macular Degeneration · United States | 2 | Terminated | Tyrogenex | Dec 12, 2017 | 157 |
| NCT01863485Advanced Cancer · China | 1 | Completed | Betta Pharmaceuticals | Oct 2014 | 44 |
| NCT01296581Neoplasms · United States | 1 | Completed | Tyrogenex | Jan 2014 | 52 |
How it is read
Names in the registry
- “EYP-1901”, 8 entries
- “CM082”, 5 entries
- “CM082 plus JS001”, 3 entries
- “vorolanib”, 2 entries
- “X-82”, 2 entries
Conditions, from the studies’ own filings
- Macular Degeneration, 7 studies
- Macular Edema, 3 studies
- Carcinoma, Renal Cell, 2 studies
- Diabetic Retinopathy, 1 study
- Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.